Petrichor

Evergreen Theragnostics Completes $26M Capital Raise to Advance Novel Radiopharmaceutical Pipeline into the Clinic, Prepare for First Commercial Product Launch, and Expand Industry-Leading CDMO Services

Retrieved on: 
Tuesday, April 16, 2024
AAA, CDMO, FDA, Petrichor, Advanced Accelerator Applications, Evergreen, Drug discovery, Patient, Education minister, Carcinoma, Pharmaceutical industry

The financing advances Evergreen's novel discovery pipeline into clinical trials, supports commercialization of its diagnostic agent, and further expands CDMO capabilities to meet growing client demand.

Key Points: 
  • The financing advances Evergreen's novel discovery pipeline into clinical trials, supports commercialization of its diagnostic agent, and further expands CDMO capabilities to meet growing client demand.
  • "We have been advancing our discovery pipeline and are excited to take the next step in development," commented James Cook, CEO.
  • In addition, our CDMO business is continuing to build momentum as we bring on new customers and expand our efforts with existing ones.
  • Our investment in Evergreen Theragnostics deepens our commitment to this exciting area with a company that is well-positioned to succeed."

Fennec Announces Incremental $5 Million Investment from Petrichor

Retrieved on: 
Tuesday, December 5, 2023
Petrichor, Risk, Sale, Hearing loss, Survivor, Cancer, TSX, FENC, Patient

RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company focused on improving the lives of children with cancer, today announced the third closing of $5 million senior secured promissory notes under the existing agreement with Petrichor. The original investment agreement provided access to up to $20 million of additional financing through December 31, 2023. As part of this closing, Fennec and Petrichor have amended the agreement to provide access to up to $15 million of additional financing through December 31, 2024.

Key Points: 
  • The original investment agreement provided access to up to $20 million of additional financing through December 31, 2023.
  • As part of this closing, Fennec and Petrichor have amended the agreement to provide access to up to $15 million of additional financing through December 31, 2024.
  • “We appreciate Petrichor’s continued support of Fennec and our efforts to grow the use of PEDMARK within the global pediatric cancer community,” said Rosty Raykov, Chief Executive Officer of Fennec.
  • Survivors of pediatric cancer should not have to additionally suffer treatment-induced hearing loss in cases where it can be safely avoided.

Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement

Retrieved on: 
Thursday, June 22, 2023
Paradigm, Interim, Autoantibody, Pfizer, Half-life, Hydra, Eye, Graves' ophthalmopathy, Petrichor, IL-6, Research, Inflammation, Antibody, Biomarker, Mergers and acquisitions, Literature, MD, Patient, DSM-IV codes, Autoimmune disease, Moyamoya disease, LP, Therapy, Death, Pharmaceutical industry, Tourmaline, ASCVD, Talari Networks, TED

BOSTON and NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris”) and Tourmaline Bio, Inc. (“Tourmaline”), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune diseases, today announced that the companies have entered into a definitive agreement under which Tourmaline will combine with Talaris in an all-stock transaction (the “Merger”). The combined company will focus on advancing Tourmaline’s lead program, TOUR006, a potentially best-in-class anti-IL-6 antibody, for the treatment of thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD). Upon completion of the Merger, the combined company will operate under the name Tourmaline Bio, Inc. and trade on the Nasdaq under the ticker symbol “TRML.” In addition, Talaris anticipates making a cash dividend of up to approximately $64.8 million to its stockholders prior to the closing of the Merger.

Key Points: 
  • Upon completion of the Merger, the combined company will operate under the name Tourmaline Bio, Inc. and trade on the Nasdaq under the ticker symbol “TRML.” In addition, Talaris anticipates making a cash dividend of up to approximately $64.8 million to its stockholders prior to the closing of the Merger.
  • Tourmaline previously completed a $112 million Series A financing in 2023 that was co-led by Deep Track Capital, Cowen Healthcare Investments, and TCGX.
  • Tourmaline was founded in September 2021 and initially financed in May 2022 by Hydra, KVP Capital, Petrichor, and QVT Family Office.
  • “We are thrilled to be entering into this transaction with Talaris,” said Sandeep Kulkarni, MD, Chief Executive Officer of Tourmaline.

Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results

Retrieved on: 
Thursday, March 30, 2023
Exercise, Insurance, Advertising, Young adult, Bank statement, New Drug Application, Food and Drug Administration, NDA, AYA, Petrichor, Research, Cisplatin, Journal of the National Comprehensive Cancer Network, NCCN, RESEARCH, FENC, Ototoxicity, Patient, Administration, Risk, Fennec, PARK, TSX, Research and development, R, FDA, Food, Adolescence, Cryptocurrency, Pharmaceutical industry, Marketing

RESEARCH TRIANGLE PARK, N.C., March 30, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today reported its financial results for the fiscal year ended December 31, 2022 and provided a business update.

Key Points: 
  • “It was an outstanding year for Fennec as we achieved FDA approval of PEDMARK® in the fourth quarter and evolved into a commercial-stage pharmaceutical company.
  • The Fennec HEARS™ program offers comprehensive patient services, including access to care coordinators, financial and prescription drug support.
  • Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2022
    Cash Position – There was a $2.7 million increase in cash and cash equivalents between December 31, 2022 and December 31, 2021.
  • The complete audited, condensed consolidated financial statements for the period ended December 31, 2022, and management's discussion and analysis of financial condition and results of operations, will be available via www.sec.gov and www.sedar.com.

Aurion Biotech Appoints Jonathan Sparks, JD, PhD as Chief Legal Officer

Retrieved on: 
Wednesday, December 7, 2022
Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Biotechnology, LLP, American Intellectual Property Law Association, Suffolk University Law School, Massachusetts Bar Association, United States patent law, Alcon, JD, Private practice, Intellectual property, Patent, Doctor of Philosophy, Petrichor, Patient, Research, Biotechnology, Endothelial dysfunction, Molecular biology, McCarter & English, Multimedia, Texas A&M University, Boston Bar Association, Toyota Aurion, Applied Genetic Technologies Corporation, Ithaca College, McCarter, Pharmaceutical industry, Biochemistry

Aurion Biotech , whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has appointed Dr. Jonathan Sparks as chief legal officer.

Key Points: 
  • Aurion Biotech , whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has appointed Dr. Jonathan Sparks as chief legal officer.
  • View the full release here: https://www.businesswire.com/news/home/20221207005300/en/
    We are delighted to welcome Jon to Aurion Biotech, said Greg Kunst, chief executive officer.
  • In addition to his role at Aurion, Dr. Jonathan Sparks is also a partner and chair of the Intellectual Property practice at McCarter & English, LLP.
  • Aurion Biotech is the recipient of the prestigious Prix Galien award for best start-up in biotech.

Aurion Biotech Expands Its Leadership Team

Retrieved on: 
Wednesday, November 30, 2022
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Optical, Science, Gilead Sciences, Takeda Pharmaceutical Company, Liberty University, Human services, Union, University, Multimedia, Purdue University, Seagen, Abbott Laboratories, BLA, Patient, BS, Regulatory affairs, Endothelial dysfunction, Biotechnology, Petrichor, American University, NDA, AMD, Alcon, Political science, Sherita Ceasar, Clinical trial, Pharmaceutical industry, Psychology, Biology

View the full release here: https://www.businesswire.com/news/home/20221130005132/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221130005132/en/
    Im delighted to welcome Sherita and Sterling to Aurion Biotech, said Greg Kunst, Aurion Biotech chief executive officer.
  • Before joining Aurion Biotech, Mr. Chung held regulatory leadership roles at Neoleukin Therapeutics, Molecular Templates, Immatics US, Seattle Genetics, Gilead Sciences, Astellas Pharmaceuticals, Takeda Pharmaceuticals, and Abbott Laboratories.
  • With offices in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies.
  • Aurion Biotech is the recipient of the prestigious Prix Galien award for best start-up in biotech.

Fennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Friday, November 11, 2022
Cisplatin, Research, FDA, R, Mission statement, Company, NASDAQ, Risk, PARK, RESEARCH, FENC, Hearing, GLOBE, TSX, Patient, Fennec, Ototoxicity, Research and development, Bridge bank, Potential, Administration, Pharmaceutical industry, Access, Petrichor

RESEARCH TRIANGLE PARK, N.C., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company focused on the development of PEDMARK® (sodium thiosulfate injection) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors today reported its financial results for the fiscal quarter ended September 30, 2022 and provided a business update.

Key Points: 
  • This was an important quarter for Fennec with the FDA approval of PEDMARK and the successful buildout of our commercial infrastructure leading to the recent U.S. commercial launch of PEDMARK.
  • In addition, we successfully completed a $25 million financing, which we believe well positions the Company for the launch of PEDMARK, said Rosty Raykov, chief executive officer of Fennec Pharmaceuticals.
  • PEDMARK provides the first and only FDA-approved treatment specifically designed to help protect hearing in children and young adults after receiving cisplatin.
  • The complete unaudited condensed consolidated financial statements for the period ended September 30, 2022 and management's discussion and analysis of financial condition and results of operations will be available via www.sec.gov and www.sedar.com.All values are presented in thousands unless otherwise noted.

Aurion Biotech Wins Prestigious Prix Galien Startup Award

Retrieved on: 
Thursday, October 27, 2022
Biotechnology, Pharmaceutical, Optical, Health, Wyeth, Ophthalmology, Endothelial dysfunction, Fortune 1000, CEO, The Hills Have Eyes 2, Endothelium, Physician, Alcon, Transplant, Paganini Competition, Patient, Petrichor, Multimedia, Cornea, Corneal transplantation, Digital health, Hoffmann-La Roche, Medicine, Former, Nobel Prize, Health, Pharmaceutical industry, Biotechnology, Incubator

Aurion Biotech , whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has won the prestigious Prix Galien Award for Best Startup in Biotech / Pharma.

Key Points: 
  • Aurion Biotech , whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has won the prestigious Prix Galien Award for Best Startup in Biotech / Pharma.
  • Aurion Biotech received the Best Start-up in Biotech / Pharma award, one of six different award categories, and was chosen from more than 146 products from 129 nominee companies, spanning 14 therapeutic areas.
  • The vetting process was rigorous: nominees are invited to apply for the Prix Galien award.
  • According to the Galien Foundation, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

Fennec Pharmaceuticals Closes First $5 Million Investment From Petrichor

Retrieved on: 
Monday, August 22, 2022
COVID-19, International investment agreement, Human, Science, Securities Act of 1933, Food and Drug Administration, Germ cell tumor, Drug Quality and Security Act, Cisplatin, U.S. Securities and Exchange Commission, Hepatoblastoma, GLOBE, Company, Risk, Potential, Patient, Medulloblastoma, EMA, Survival, Contagious disease, Sale, Incidence, RESEARCH, Food, SEC, Instability, Bridge bank, FDA, Platinum, CRL, Hearing loss, COG, Cancer, Ototoxicity, FENC, Security (finance), NDA, Sumathi Best Television Current Reporting Award, NASDAQ, Survivor, PDUFA, MAA, Literacy, Investment, Patent, PARK, Disease, Osteosarcoma, STS, Coronavirus, Fennec, OHSU, Health, TSX, Goal, Neuroblastoma, Kool-Aid, Failure, Annual report, Forward-looking statement, Pharmaceutical industry, Nasdaq, Petrichor, Access

RESEARCH TRIANGLE PARK, N.C., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced it has completed the first closing of US$5 million of senior secured promissory notes under our previously announced investment agreement with Petrichor Healthcare Capital Management. Under the terms of the investment agreement, an additional $20 million is to be funded upon the potential U.S. Food and Drug Administration (FDA) approval of PEDMARKTM by September 30, 2022 and satisfaction of other closing conditions. Further, Fennec upon mutual agreement with Petrichor may draw up to $20 million of additional financing under the investment agreement.

Key Points: 
  • Further, Fennec upon mutual agreement with Petrichor may draw up to $20 million of additional financing under the investment agreement.
  • Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development of PEDMARKfor the prevention of platinum-induced ototoxicity in pediatric patients.
  • The Petrichor has completed over 90 investments representing more than$5 billionin invested capital and has held over 30 board seats.
  • If the FDA does not approve the NDA resubmission of PEDMARK, we will not have access to the Petrichor financing.

Fennec Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Friday, August 12, 2022
FDA, PDUFA, Cisplatin, Literacy, Survival, Contagious disease, Risk, NDA, Cancer, Forward-looking statement, OHSU, Hepatoblastoma, Neuroblastoma, Failure, European Medicines Agency, Oregon Health & Science University, CRL, Incidence, Patent, Security (finance), Annual report, Patient, Instability, COVID-19, Company, MAA, Medulloblastoma, U.S. Securities and Exchange Commission, COG, Coronavirus, Exchange, Fennec, Survivor, Hearing loss, Ototoxicity, Petrichor, Disease, Goal, Platinum, Osteosarcoma, Human, Kool-Aid, Germ cell tumor, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, STS, Food, EMA, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its financial results for the fiscal quarter ended June 30, 2022 and provided a business update.

Key Points: 
  • The incidence of ototoxicity depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing aids.
  • Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development of PEDMARK for the prevention of platinum-induced ototoxicity in pediatric patients.
  • Fennec disclaims any obligation to update these forward-looking statements except as required by law.
  • For a more detailed discussion of related risk factors, please refer to our public filings available at www.sec.gov and www.sedar.com.